Olio Labs

Company Overview

Olio Labs is a healthcare company that operates fully remotely. Founded in 2023, Olio Labs specializes in the drug discovery and delivery sub-industry. The company is part of Y Combinator's Summer 2023 batch. Their primary focus is on developing combination therapeutics targeting obesity with fewer side effects than existing treatments like Ozempic.

Industry and Specialization

Olio Labs operates within the healthcare industry, specifically focusing on drug discovery and delivery. The company's innovation includes using artificial intelligence to develop combination therapeutics designed to treat obesity. Their approach aims to find optimal therapeutic combinations with reduced side effects.

Technological Approach

Olio Labs leverages custom machine learning models built from real-world expertise and cutting-edge AI. Their technology is designed to search through trillions of combinations to identify the most effective therapeutic solutions. This advanced AI-driven approach distinguishes Olio Labs in the drug discovery and delivery sector.

Company Launch and Y Combinator Involvement

Launched in 2023, Olio Labs is part of Y Combinator's Summer 2023 (S23) batch. This involvement has provided the company with significant backing and resources, facilitating its growth and development in the competitive healthcare landscape.

Contact Information

Olio Labs welcomes inquiries and can be contacted via email at hello@oliolabs.co. The company operates fully remotely, making it accessible from any location around the world.

Report inaccurate information

Companies similar to Olio Labs

Alfie, formerly known as MIST, is a healthcare company based in New York offering a virtual medical program for weight loss, leveraging research from Cleveland Clinic and Harvard. The program is notably more effective than traditional methods and accepts most insurances in select states.

Medium Biosciences, based in Boston, MA, is a healthcare company focusing on industrial bio, developing AI models to innovate biomolecule performance.

Output Biosciences, formerly known as Jingu Health, is a New York-based healthcare company focused on extending human healthspan by developing preventative therapies using computational biology and AI.

Mindstate Design Labs, formerly known as Kykeon Biotechnologies, is a healthcare company specializing in the development of psychedelic therapeutics for mental health, utilizing AI and machine learning.

Persist AI, based in Woodland, CA, specializes in using AI-driven automation to halve the development time for long-lasting drug injections, focusing on chronic diseases such as cancer and diabetes.

Nanograb, based in San Francisco and London, is a healthcare company specializing in drug discovery and delivery using AI to create targeted treatments. The team of three scientists, with extensive experience in antibody design, participated in Y Combinator's S23 batch and launched in 2023.

Known Medicine, based in Salt Lake City, Utah, combines patient-specific 3D cell culture and AI to enhance drug translation to clinical success in the oncology sector. The company, founded in 2020 and part of Y Combinator's S20 batch, develops predictive technologies for personalized cancer treatment.

Atomwise, based in San Francisco, CA, leverages artificial intelligence to revolutionize drug discovery, focusing on small-molecule drug candidates in immunology and oncology.

Insitro is a biotechnology company that leverages machine learning and large-scale data analysis to expedite drug discovery and development, focusing on metabolism, oncology, and neuroscience.

METiS Therapeutics, launched with $86 million in Series A financing, focuses on using AI and machine learning to revolutionize drug discovery and delivery, targeting small molecules, biologics, and nucleic acids.